MARKET

DYAI

DYAI

Dyadic Intl Inc Del
NASDAQ
1.670
+0.040
+2.45%
Closed 16:00 03/28 EDT
OPEN
1.640
PREV CLOSE
1.630
HIGH
1.730
LOW
1.640
VOLUME
29.73K
TURNOVER
0
52 WEEK HIGH
2.400
52 WEEK LOW
1.190
MARKET CAP
48.11M
P/E (TTM)
-6.9816
1D
5D
1M
3M
1Y
5Y
Dyadic International Inc reports results for the quarter ended in December - Earnings Summary
Dyadic International Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 8 cents per share. Revenue fell 7.7% to $687.00 thousand from a year ago. Dyadic International shares had risen by 1.2% this quarter.
Reuters · 4h ago
Recap: Dyadic International Q4 Earnings
Dyadic International reported its Q4 earnings on March 28, 2024. Dyadic International missed estimated earnings by -33.0%. The company's revenue was down $57 thousand from the same period last year. The company is expected to announce its earnings on April 28.
Benzinga · 4h ago
Dyadic International Announces Key Leadership Changes
TipRanks · 5h ago
Dyadic International GAAP EPS of -$0.24 misses by $0.01, revenue of $2.9M misses by $0.15M
Earnings News Dyadic International GAAP EPS of -$0.24 misses by $0.01, revenue of $2.9M misses by $ 0.15M. Dyadic international, Inc. (DYAI) expected to report its quarterly results on Mar. 28, 2024.
Seeking Alpha · 5h ago
Press Release: Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic Reports 2023 Full Year Results and Recent Company Progress. Dyadic reports positive topline data from First-In-Human Phase 1 trial for DYAI-100 vaccine. Company closed a $6.0 million convertible note in a private placement. Company has entered into several fully funded vaccine and antibody projects.
Dow Jones · 5h ago
Press Release: Dyadic Reports 2023 Full Year -3-
Dyadic's gene expression and protein production platforms are based on the fungus Thermothelomyces heterothallica. Dyadic's lead technology, the C1-cell protein production platform, is used to speed development of biologic vaccines and drugs for the human and animal health markets. The company is building an active pipeline to advance its microbial platform technologies.
Dow Jones · 5h ago
After-Hours Earnings Report for March 28, 2024 : ACHV, ACNT, AREC, AXDX, CPTN, CURV, DARE, DNMR, DYAI, FORA, HSDT, INLX
NASDAQ · 7h ago
Dyadic's Michael Tarnok to step down as Chairman of the board of directors
Dyadic's Michael Tarnok to step down as Chairman of the board of directors. Patrick Lucy has been appointed to succeed him, effective immediately. Dyadic's Barry Buckland announced he is retiring and will not stand for re-election to the board in 2024.
Seeking Alpha · 12h ago
More
About DYAI
Dyadic International, Inc. is a global biotechnology platform company with operations in the United States. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for industrial applications. This technology is based on the Thermothelomyces heterothallica fungus, namely C1. The C1-cell protein production platform is a robust and versatile thermophilic filamentous fungal expression system for the development and production of biologic products, including enzymes and other proteins for human and animal health. The Company also developed the Dapibus thermophilic filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of proteins, metabolites and other biologic products for use in non-pharmaceutical applications, such as food, nutrition and wellness.

Webull offers Dyadic International Inc stock information, including NASDAQ: DYAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYAI stock methods without spending real money on the virtual paper trading platform.